Last updated on November 2018

Immunoadsorption for Treatment of Alzheimer's Disease


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Alzheimer Dementia
  • Age: Between 55 - 85 Years
  • Gender: Male or Female

Inclusion Criteria:

  • 55-85 years of age
  • Diagnosis of Alzheimer's disease
  • Presence of agAAB against alpha1-adrenoceptor
  • Mini mental state examination (MMSE) score between 19 and 26
  • Written informed consent given

Exclusion Criteria:

  • Haemanalysis:
  • Presence of autoantibodies against the N-methyl-D-aspartate (NMDA) receptor
  • Defective blood coagulation at time of inclusion
  • Severe protein deficiency disorders
  • manifest Vitamin/Folic acid deficiency (substitution allowed)
  • Active infectious disease, or signs of ongoing infection with C-reactive protein (CRP) >10mmol/L
  • Impaired renal function (serum creatinine >220 mol/L)
  • Any disease requiring immunosuppressive drugs or therapeutic antibodies
  • Non curative treated malignant disease or another life-threatening disease with poor prognosis (survival less than 2 years), except for basal-cell carcinoma
  • Unstable angina pectoris, atrioventricular block (AV block) 2./3. degree or symptomatic sick sinus syndrome without implanted pacemaker, history of myocardial infarct, bypass or other revascularization measures, valvular heart defect ( 2. Degree)
  • Severely reduced left ventricular systolic function (LVEF < 30%) and/or heart failure symptoms according to New York Heart Association (NYHA) class III/IV
  • Clinical manifestation of arterial disease, vascular surgery: No Arteria Carotis Interna (ACI) Stenosis > 60%, peripheral artery occlusive disease (PAOD) > IIb, NASCET, no clinical manifest apparent stroke in anamnesis, MRI: no diffusion disorder, no expired territorial stroke
  • Endocrine disorder excluding diabetes mellitus
  • Severe hepatic damages (CHILD-Score < 4)
  • Severe mental disorders (bipolar disorder, schizophrenia, depression) requiring treatment
  • Alcohol or drug abuse
  • Drug therapy against dementia since less than 3 months
  • Psychopharmacological drug therapy since less than 3 months
  • Dialysis requirement
  • MRI contraindications (e.g. heart pacemaker)
  • Legal tutelage
  • Previous treatments with IA or immunoglobulin
  • Inability to undergo the study procedure (IA on five consecutive days with subsequent Immunoglobulin G (IgG) substitution)
  • treatment with angiotensin-converting-enzyme inhibitors (ACE inhibitors) during the IA (angiotensin receptor blockers (AT-blockers) possible)
  • Participation in any other clinical/interventional study within less than 30 days prior to screening date

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.